Copied from Dalts66 post at 6am todayUSE OF PROCEEDSWe expect to...

Copied from Dalts66 post at 6am today

USE OF PROCEEDS
We expect to receive approximately $500 million from the sale of shares of our common stock offered hereby before deducting underwriting discounts and commissions and estimated offering expenses payable by us, or approximately $575 million if the underwriters exercise their option in full to purchase up to $75 million of additional shares of our common stock. We intend to use the net proceeds from this offering principally for the continuation of, and initiation of further, clinical trials, commercialization, manufacturing, business development activities, including the potential licensing or acquisition of complementary products, technologies and entities, and other general corporate purposes. The amounts and timing of our actual expenditures for each purpose may vary significantly depending upon numerous factors, including the status of our product development and clinical trial efforts, regulatory approvals, competition and our ability to obtain government funding or other non-dilutive financing for the development of certain of our product candidates. We reserve the right to change the use of proceeds as a result of certain contingencies, such as competitive developments, opportunities to acquire technologies, products or entities and other factors. Pending application, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing instruments.

Note the line: including the potential licensing or acquisition of complementary products